Navigation Links
AstraZeneca and UCL to collaborate to develop regenerative medicines for diabetic retinopathy
Date:9/13/2010

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

DR is now the most common cause of vision impairment among those of working age in Western society. The majority of patients with type 1 diabetes will develop retinopathy and about 20-30% will become blind. Moreover, a large number of patients with type 2 diabetes will develop retinopathy as their underlying disease progresses. With the global epidemic of type 2 diabetes, this predicament is set to worsen as over 438 million people are projected to suffer from diabetes and its complications by 2030.

Under the terms of the three-year agreement, AstraZeneca and scientists at the UCL Institute of Ophthalmology will collaborate to identify new therapeutic tools that can modulate the regenerative capacity of stem cells. Dr Marcus Fruttiger, UCL Institute of Ophthalmology, is leading the project and explains that, "These tools could be used either to manufacture transplantable material or to directly stimulate new cell growth in the eye to help restore or improve the vision of those with DR."

"AstraZeneca believes that regenerative medicine offers new opportunities to develop innovative, more effective and safer therapies to benefit patient health. Over the next few years, stem cell technology is likely to contribute to a measurable improvement in our ability to discover and develop candidate drugs, and to target those drugs to the right patient population through a better understanding of the disease process. We are delighted to be combining our drug hunting expertise with the pioneering research ongoing at UCL," said Alan Lamont, Director of Sciences and Technology Alliances at AstraZeneca .

Professor Pete Coffey, UCL Institute of Ophthalmology, adds: "This is a great collaborative opportunity and we're delighted to be working with AstraZeneca to explore the potential of harnessing the regenerative capacity of stem cells to develop a cellular therapy for diabetic retinopathy, which is a major cause of visual impairment and blindness worldwide. AstraZeneca has a proven track record in developing medicines and their involvement in this type of research is very exciting."


'/>"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-788-183-3274
University College London
Source:Eurekalert

Related medicine news :

1. AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
2. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
3. Gladstone and Lundbeck collaborate to study neurovascular disease
4. Anakam And Axolotl Collaborate To Deliver A Multi-Factor Authentication Platform For Santa Cruz Health Information Exchange
5. UCLA researchers, US military collaborate to open center for traumatic brain injury
6. Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution
7. Carefx to Collaborate with the Cleveland Clinic to Commercialize CCF Business Intelligence Solution
8. Two Hand Therapy Organizations Collaborate on Jam-Packed Educational Weekend
9. BCS Global and Iformata Sign Agreement to Collaborate on the PSVN Initiative to Deliver B2B Video Communications
10. PeopleStreme Collaborates with SkillSoft for Learning Management Content
11. Doctors must collaborate so that patients get full benefit of tamoxifen treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual ... City. He is known for his distinguished expertise and experience in the diagnosis and ... sub-specialty training in treating renovascular disease and aortic aneurysm . He is known ...
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ... interpretation, has received U.S. Food and Drug Administration (FDA) 510(k) clearance ... and secure cloud platform for medical image management. At the core is patented ...
(Date:5/24/2017)... ... 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now ... a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take ... Patients no longer need to feel the esthetic effects of wires and brackets when ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New Foundation for ... that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, and destroys ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As ... latest advancements in his field by attending numerous CE courses each year. His ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
Breaking Medicine Technology: